Aprogen Pharmaceuticals Inc (003060) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has a cash flow conversion efficiency ratio of -0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-7.66 Billion ≈ $-5.19 Million USD) by net assets (₩315.16 Billion ≈ $213.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 003060 market cap for the company's overall valuation and market capitalisation.
Aprogen Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aprogen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Aprogen Pharmaceuticals Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Young Fast Optoelectronics Co Ltd
TW:3622
|
0.016x |
|
CyberTAN Technology Inc
TW:3062
|
-0.071x |
|
Zentalis Pharmaceuticals Llc
NASDAQ:ZNTL
|
-0.143x |
|
Grupo Industrial Saltillo S.A.B. de C.V
MX:GISSAA
|
0.008x |
|
Highlight Tech
TWO:6208
|
0.040x |
|
Rani Zim Shopping Centers
TA:RANI
|
0.015x |
|
EMS Limited
NSE:EMSLIMITED
|
-0.029x |
|
Montana Technologies Corporation
NASDAQ:AIRJ
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Aprogen Pharmaceuticals Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Aprogen Pharmaceuticals Inc from 2010 to 2024. View 003060 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩378.69 Billion ≈ $256.63 Million |
₩-31.00 Billion ≈ $-21.01 Million |
-0.082x | +10.32% |
| 2023-12-31 | ₩368.69 Billion ≈ $249.86 Million |
₩-33.65 Billion ≈ $-22.80 Million |
-0.091x | -281.07% |
| 2022-12-31 | ₩510.41 Billion ≈ $345.90 Million |
₩25.73 Billion ≈ $17.44 Million |
0.050x | +583.45% |
| 2021-12-31 | ₩597.18 Billion ≈ $404.70 Million |
₩-6.23 Billion ≈ $-4.22 Million |
-0.010x | -177.13% |
| 2020-12-31 | ₩598.36 Billion ≈ $405.50 Million |
₩8.09 Billion ≈ $5.48 Million |
0.014x | +558.38% |
| 2019-12-31 | ₩347.64 Billion ≈ $235.59 Million |
₩713.73 Million ≈ $483.69K |
0.002x | -76.79% |
| 2018-12-31 | ₩150.51 Billion ≈ $102.00 Million |
₩1.33 Billion ≈ $902.26K |
0.009x | +107.71% |
| 2017-12-31 | ₩77.86 Billion ≈ $52.77 Million |
₩-8.93 Billion ≈ $-6.05 Million |
-0.115x | -2090.66% |
| 2016-12-31 | ₩78.12 Billion ≈ $52.94 Million |
₩449.98 Million ≈ $304.95K |
0.006x | -78.87% |
| 2015-12-31 | ₩67.75 Billion ≈ $45.91 Million |
₩1.85 Billion ≈ $1.25 Million |
0.027x | +124.48% |
| 2014-12-31 | ₩62.11 Billion ≈ $42.09 Million |
₩-6.92 Billion ≈ $-4.69 Million |
-0.111x | -270.03% |
| 2013-12-31 | ₩56.55 Billion ≈ $38.32 Million |
₩-1.70 Billion ≈ $-1.15 Million |
-0.030x | -619.64% |
| 2010-12-31 | ₩42.81 Billion ≈ $29.01 Million |
₩247.92 Million ≈ $168.01K |
0.006x | -- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.